EUCTR2012-004053-88-SE进行中（未招募）1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C2
Justus-Liebig-University Giessen0 个研究点目标入组 2,200 人开始时间: 2018年6月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Histologically confirmed primary diagnosis of classical Hodgkin’s lymphoma
- •Patients under 18 years of age on the date of written informed consent. In specialised Teenage and Young Adult (TYA) units in Australia, France, Italy,
- •New Zealand and UK patients up to under 25 years of age can also be enrolled. Lower age limits will be country specific according to national laws or formal insurance requirements that may preclude very young patients.
- •Written informed consent of the patient and/or the patient’s parents or guardian according to national laws
- •Negative pregnancy test within 2 weeks prior to starting treatment for female patients with childbearing potential
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2200
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior chemotherapy or radiotherapy for other malignancies
- •Pre-treatment of Hodgkin’s lymphoma (except for 7-10 days steroid pre-phase of a large mediastinal tumour)
- •Diagnosis of lymphocyte-predominant Hodgkin’s lymphoma
- •Other (simultaneous) malignancies
- •Contraindication or known hypersensitivity to study drugs
- •Severe concomitant diseases (e.g. immune deficiency syndrome)
- •Known HIV-positivity
- •Residence outside the participating countries where long term follow-up cannot be guaranteed
- •Pregnancy and/or lactation
- •Patients who are sexually active and are unwilling to use adequate contraception during therapy and for one year after last trial treatment
- •Current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another
- •interventional clinical trial
研究者
相似试验
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C1EUCTR2006-000995-33-DKMartin-Luther-University Halle-Wittenberg25
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C11st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.MedDRA version: 8.1 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's diseaseEUCTR2006-000995-33-DEMartin-Luther-University Halle-Wittenberg1,200
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin?s Lymphoma Group First international Inter-Group Study for classical Hodgkin?s Lymphoma in Children and Adolescents - EuroNet-PHL-C11st and 2nd line therapy for childhood Hodgkin?s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.MedDRA version: 8.1 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's diseaseEUCTR2006-000995-33-NLMartin-Luther-University Halle-Wittenberg1,200
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.EUCTR2007-004092-19-CZMartin Luther University of Halle/Wittenberg250
进行中（未招募）
1 期
Evaluation of the therapy of Hodgkin’s Lymphoma in Children and AdolescentsEUCTR2007-004092-19-DEMartin Luther University of Halle/Wittenberg200